Manage Account
Change Password
Sign Out
UserName
Profession Email
Profession Email
|
Indications/Uses
CHF.
|
|
Dosage/Direction for Use
Adult : IV Loading dose: 6-24 mcg/kg over 10 min, then 0.05-0.2 mcg/kg/min continuous infusion.
|
|
Dosage Details
Intravenous
Congestive heart failure Adult: Loading dose: 6-24 mcg/kg over 10 min followed by 0.05-0.2 mcg/kg/min continuous infusion, adjust according to response.
|
|
Renal Impairment
Severe: Contraindicated.
|
|
Hepatic Impairment
Severe: Contraindicated.
|
|
Contraindications
History of torsade de pointes. Severe renal and hepatic impairment.
|
|
Special Precautions
Patient w/ severe hypotension, tachycardia or w/ mechanical obstruction affecting ventricular filling or outflow; ongoing coronary ischaemic or long QTc interval. Renal and hepatic impairment.
|
|
Adverse Reactions
Headache, dizziness, hypotension, ventricular tachycardia, extrasystoles, AF, hypokalaemia, insomnia, GI disturbances and anaemia.
Potentially Fatal: Arrhythmias, tachycardia, AF w/ rapid ventricular response. |
|
MonitoringParameters
Closely monitor ECG, serum K concentration. Monitor haemodynamic effects for several days after the end of infusion as they may be prolonged.
|
|
Action
Description: Levosimendan is a cardiac inotrope and vasodilator w/ Ca-sensitising properties. It is dependent on Ca concentration and sensitises tropin C to Ca. It also opens ATP-sensitive K channels on vascular smooth muscle which causes coronary and systemic vasodilation.
Pharmacokinetics: Absorption: Well absorbed. Bioavailability: 85%. Time to peak plasma concentration: 1-2 days. Distribution: Plasma protein binding: Approx 98% (mainly albumin); approx 40% (active metabolite). Metabolism: Extensively metabolised to its active metabolite (OR-1855 and OR-1896) which are interconverted by acetylation and de-acetylation. Excretion: Via urine and faeces as metabolites and unchanged drug (small amount). Elimination half-life: Approx 1 hr. |
|
MIMS Class
|
